Oncobiomix, a provider in prostate cancer assessment profiles using microbiome risk scores, has selected Limmi’s Disease Insights Platform to power its new test. Limmi is an AI startup dedicated to transforming patient outcomes by rapidly discovering hidden patterns in life sciences data, the company says.
Limmi utilizes AI and deep learning methodologies on a platform built specifically for healthcare and biotech, offering their customers real-time predictions and insights to patients, designed to radically change the way their customers manage healthcare operations and patient health management.
Oncobiomix’s mission is to empower patients with personalized data acquired from their own microbiome, the company says. The microbiome is the microbes that live on and within us. There are nearly as many bacteria that live in our gut as we have human cells in our body. The microbes can have connections to our genetics, immune system, exposures, diet, and many other functions. Oncobiomix has developed artificial intelligence methods to provide analysis of the complex connections within the microbiome data as it relates to disease. This is a technology that could unlock clues that could revolutionize personalized approaches to health.
Further reading: Blood Test Distinguishes Neuroendocrine Subtype of Advanced Prostate Cancer
“Limmi’s disease insights platform will drastically reduce our time to market and give us the ability to continuously improve our AI models,” says Michael Liss, MD, PhD, MAS, FACS, founder of Oncobiomix and professor and chief of the Division of Urologic Oncology in the Department of Urology at the University of Texas Health Science Center San Antonio. “Our partnership with Limmi combined with our revolutionary microbiome risk prediction biomarker is poised to transform how we think about cancer risk, starting with prostate cancer.”
Oncobiomix will use Limmi’s Disease Insights Platform to power their AI models for predicting prostate cancer risk. The platform will be used to trained additional improved models for prostate cancer risk as well as other cancer risk profiles as Oncobiomix adds new IP to their portfolio of risk detection diagnostics.
“With Oncobiomix’s AI powered microbiome risk profile platform, we are confident our partnership will yield tremendous results,” says Bryan Ivory, Limmi president and chief technology offficer. “We are proud to help Oncobiomix enhance microbiome-based disease risk predictions, by sifting through the large genetic datasets and providing new AI models and insights that continuously learn and improve over time.”
